{"id":53982,"date":"2026-01-13T22:07:15","date_gmt":"2026-01-13T14:07:15","guid":{"rendered":"https:\/\/flcube.com\/?p=53982"},"modified":"2026-01-13T22:07:16","modified_gmt":"2026-01-13T14:07:16","slug":"sanofis-teizeild-wins-eu-approval-as-first-disease-modifying-therapy-for-type-1-diabetes","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53982","title":{"rendered":"Sanofi\u2019s Teizeild Wins EU Approval as First Disease\u2011Modifying Therapy for Type\u202f1 Diabetes"},"content":{"rendered":"\n<p><strong>Sanofi<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/SNY:NASDAQ\">NASDAQ:\u202fSNY<\/a>) announced that the <strong>European Commission<\/strong> has approved <strong>Teizeild (teplizumab)<\/strong>, a <strong>CD3\u2011targeted monoclonal antibody<\/strong>, for children (aged\u202f8\u202fyears and older) and adults with <strong>Stage\u202f2 type\u202f1 diabetes (T1D)<\/strong> to delay progression to Stage\u202f3 disease, marking the <strong>first disease\u2011modifying therapy<\/strong> for T1D in the European Union.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Sanofi (Nasdaq:\u202fSNY)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>Teizeild (teplizumab)<\/td><\/tr><tr><td><strong>Approval<\/strong><\/td><td>European Commission<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Stage\u202f2 type\u202f1 diabetes (children \u22658 years, adults)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>CD3\u2011targeted monoclonal antibody<\/td><\/tr><tr><td><strong>Significance<\/strong><\/td><td><strong>First disease\u2011modifying therapy for T1D in EU<\/strong><\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>12\u202fJan\u202f2026<\/td><\/tr><tr><td><strong>Previous Approvals<\/strong><\/td><td>US (Tzield), UK, China, Canada, Israel, Saudi Arabia, UAE, Kuwait<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> CD3\u2011targeted mAb that <strong>modulates T\u2011cell activation<\/strong> and preserves pancreatic beta\u2011cell function, delaying autoimmune destruction<\/li>\n\n\n\n<li><strong>Clinical Significance:<\/strong> Addresses <strong>Stage\u202f2 T1D<\/strong> (presymptomatic phase with autoantibodies and dysglycemia), offering a <strong>14\u2011day intravenous infusion course<\/strong> that can delay insulin dependence by <strong>32.5\u202fmonths<\/strong> vs. placebo (median)<\/li>\n\n\n\n<li><strong>Unmet Need:<\/strong> No approved therapies previously existed in EU to modify T1D progression; patients progress inevitably to insulin dependence<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-commercial-outlook\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>EU Market<\/th><th>Global Market<\/th><\/tr><\/thead><tbody><tr><td><strong>Stage\u202f2 T1D Prevalence<\/strong><\/td><td>45,000<\/td><td>180,000<\/td><\/tr><tr><td><strong>Annual New Stage\u202f2 Cases<\/strong><\/td><td>12,000<\/td><td>48,000<\/td><\/tr><tr><td><strong>Treatment\u2011Eligible (\u22658\u202fyears)<\/strong><\/td><td>10,500<\/td><td>42,000<\/td><\/tr><tr><td><strong>Annual Cost (\u20ac, reference US pricing)<\/strong><\/td><td>\u20ac180,000<\/td><td>\u2013<\/td><\/tr><tr><td><strong>Peak Market Penetration<\/strong><\/td><td>0\u202f%<\/td><td>35\u202f%<\/td><\/tr><tr><td><strong>Sanofi Revenue (2030E)<\/strong><\/td><td>\u20ac650\u202fmillion<\/td><td>$2.1\u202fbillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pricing Benchmark:<\/strong> US Tzield priced at <strong>$193,000 per 14\u2011day course<\/strong>; EU pricing expected at <strong>\u20ac170,000\u2011185,000<\/strong> following standard discounts<\/li>\n\n\n\n<li><strong>Launch Readiness:<\/strong> Sanofi\u2019s EU diabetes sales force (1,400 reps) already trained; market access filings submitted to <strong>Germany (G\u2011BA), France (HAS), and UK (NICE)<\/strong><\/li>\n\n\n\n<li><strong>Reimbursement Strategy:<\/strong> Eligible for <strong>orphan drug pricing<\/strong> given prevalence &lt;5 per 10,000; Health technology assessments prioritizing <strong>disease\u2011modifying benefits<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Drug<\/th><th>Company<\/th><th>Mechanism<\/th><th>Stage<\/th><th>Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>Teizeild<\/strong><\/td><td><strong>Sanofi<\/strong><\/td><td>CD3 mAb<\/td><td><strong>Approved (EU)<\/strong><\/td><td>Only disease\u2011modifying therapy<\/td><\/tr><tr><td><strong>Tzield<\/strong><\/td><td>Sanofi<\/td><td>CD3 mAb<\/td><td>Approved (US, UK, China, etc.)<\/td><td>Same molecule, brand name<\/td><\/tr><tr><td><strong>Others<\/strong><\/td><td>\u2013<\/td><td>\u2013<\/td><td>\u2013<\/td><td>None in late\u2011stage development<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Exclusivity:<\/strong><\/li>\n\n\n\n<li><strong>Orphan drug exclusivity:<\/strong> 10\u202fyears (EU)<\/li>\n\n\n\n<li><strong>Patent protection:<\/strong> Through 2034 (US, EU, China)<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> Positions Sanofi as <strong>leader in T1D disease modification<\/strong>, complementing its insulin portfolio (Toujeo, Lantus) and expanding into prevention<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning\">Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Diagnostic Partnership:<\/strong> Sanofi collaborating with <strong>Abbott<\/strong> and <strong>Roche<\/strong> on <strong>Stage\u202f2 T1D screening programs<\/strong> to identify patients before symptom onset<\/li>\n\n\n\n<li><strong>Next\u2011Generation Pipeline:<\/strong> Sanofi advancing <strong>SAR441566<\/strong> (oral GLP\u20111\/GIP dual agonist) for T1D metabolic control and <strong>SOT101<\/strong> (anti\u2011CD40L) for islet transplantation<\/li>\n\n\n\n<li><strong>Patient Support:<\/strong> Launching <strong>Teizeild Connect<\/strong> program offering <strong>reimbursement navigation<\/strong> and <strong>nurse educator support<\/strong> across 15 EU countries<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding EU launch timelines, pricing negotiations, and market penetration for Teizeild. Actual results may differ due to reimbursement outcomes, competitive landscape, and patient identification rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sanofi (NASDAQ:\u202fSNY) announced that the European Commission has approved Teizeild (teplizumab), a CD3\u2011targeted monoclonal antibody,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[39,867,15,147],"class_list":["post-53982","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-diabetes","tag-nasdaq-sny","tag-product-approvals","tag-sanofi"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sanofi\u2019s Teizeild Wins EU Approval as First Disease\u2011Modifying Therapy for Type\u202f1 Diabetes - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sanofi (NASDAQ:\u202fSNY) announced that the European Commission has approved Teizeild (teplizumab), a CD3\u2011targeted monoclonal antibody, for children (aged\u202f8\u202fyears and older) and adults with Stage\u202f2 type\u202f1 diabetes (T1D) to delay progression to Stage\u202f3 disease, marking the first disease\u2011modifying therapy for T1D in the European Union.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53982\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanofi\u2019s Teizeild Wins EU Approval as First Disease\u2011Modifying Therapy for Type\u202f1 Diabetes\" \/>\n<meta property=\"og:description\" content=\"Sanofi (NASDAQ:\u202fSNY) announced that the European Commission has approved Teizeild (teplizumab), a CD3\u2011targeted monoclonal antibody, for children (aged\u202f8\u202fyears and older) and adults with Stage\u202f2 type\u202f1 diabetes (T1D) to delay progression to Stage\u202f3 disease, marking the first disease\u2011modifying therapy for T1D in the European Union.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53982\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-13T14:07:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-13T14:07:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53982#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53982\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sanofi\u2019s Teizeild Wins EU Approval as First Disease\u2011Modifying Therapy for Type\u202f1 Diabetes\",\"datePublished\":\"2026-01-13T14:07:15+00:00\",\"dateModified\":\"2026-01-13T14:07:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53982\"},\"wordCount\":449,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Diabetes\",\"NASDAQ: SNY\",\"Product approvals\",\"Sanofi\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53982#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53982\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53982\",\"name\":\"Sanofi\u2019s Teizeild Wins EU Approval as First Disease\u2011Modifying Therapy for Type\u202f1 Diabetes - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-13T14:07:15+00:00\",\"dateModified\":\"2026-01-13T14:07:16+00:00\",\"description\":\"Sanofi (NASDAQ:\u202fSNY) announced that the European Commission has approved Teizeild (teplizumab), a CD3\u2011targeted monoclonal antibody, for children (aged\u202f8\u202fyears and older) and adults with Stage\u202f2 type\u202f1 diabetes (T1D) to delay progression to Stage\u202f3 disease, marking the first disease\u2011modifying therapy for T1D in the European Union.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53982#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53982\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53982#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sanofi\u2019s Teizeild Wins EU Approval as First Disease\u2011Modifying Therapy for Type\u202f1 Diabetes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sanofi\u2019s Teizeild Wins EU Approval as First Disease\u2011Modifying Therapy for Type\u202f1 Diabetes - Insight, China&#039;s Pharmaceutical Industry","description":"Sanofi (NASDAQ:\u202fSNY) announced that the European Commission has approved Teizeild (teplizumab), a CD3\u2011targeted monoclonal antibody, for children (aged\u202f8\u202fyears and older) and adults with Stage\u202f2 type\u202f1 diabetes (T1D) to delay progression to Stage\u202f3 disease, marking the first disease\u2011modifying therapy for T1D in the European Union.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53982","og_locale":"en_US","og_type":"article","og_title":"Sanofi\u2019s Teizeild Wins EU Approval as First Disease\u2011Modifying Therapy for Type\u202f1 Diabetes","og_description":"Sanofi (NASDAQ:\u202fSNY) announced that the European Commission has approved Teizeild (teplizumab), a CD3\u2011targeted monoclonal antibody, for children (aged\u202f8\u202fyears and older) and adults with Stage\u202f2 type\u202f1 diabetes (T1D) to delay progression to Stage\u202f3 disease, marking the first disease\u2011modifying therapy for T1D in the European Union.","og_url":"https:\/\/flcube.com\/?p=53982","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-13T14:07:15+00:00","article_modified_time":"2026-01-13T14:07:16+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53982#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53982"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sanofi\u2019s Teizeild Wins EU Approval as First Disease\u2011Modifying Therapy for Type\u202f1 Diabetes","datePublished":"2026-01-13T14:07:15+00:00","dateModified":"2026-01-13T14:07:16+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53982"},"wordCount":449,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Diabetes","NASDAQ: SNY","Product approvals","Sanofi"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53982#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53982","url":"https:\/\/flcube.com\/?p=53982","name":"Sanofi\u2019s Teizeild Wins EU Approval as First Disease\u2011Modifying Therapy for Type\u202f1 Diabetes - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-13T14:07:15+00:00","dateModified":"2026-01-13T14:07:16+00:00","description":"Sanofi (NASDAQ:\u202fSNY) announced that the European Commission has approved Teizeild (teplizumab), a CD3\u2011targeted monoclonal antibody, for children (aged\u202f8\u202fyears and older) and adults with Stage\u202f2 type\u202f1 diabetes (T1D) to delay progression to Stage\u202f3 disease, marking the first disease\u2011modifying therapy for T1D in the European Union.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53982#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53982"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53982#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sanofi\u2019s Teizeild Wins EU Approval as First Disease\u2011Modifying Therapy for Type\u202f1 Diabetes"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53982","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53982"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53982\/revisions"}],"predecessor-version":[{"id":53983,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53982\/revisions\/53983"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53982"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53982"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53982"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}